Sign In
Buy VNDA
$5.10
-0.0800 (-1.54%)
At Close: Jul 31, 2026
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates
06:10pm, Wednesday, 07'th May 2025
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.07 per share a year ago.
Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results
04:01pm, Wednesday, 07'th May 2025
Fanapt® Q1 2025 total prescriptions (TRx) increased 14% compared to Q1 2024 Fanapt® Q1 2025 new to brand prescriptions (NBRx) increased nearly threefold compared to Q1 2024 Bysanti™ (milsaperidon
Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026
08:00am, Monday, 05'th May 2025
WASHINGTON , May 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) informed Vanda that the New Drug Application
Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025
08:46am, Friday, 02'nd May 2025
Conference Call and Webcast to Follow WASHINGTON , May 2, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2025 on W
FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA
03:52pm, Wednesday, 23'rd Apr 2025
WASHINGTON , April 23, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) today announced that FDA bureaucrats have committed to delay Vanda's request for a hearing on the appro
Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting
08:00am, Monday, 07'th Apr 2025
WASHINGTON , April 7, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at the American Academy of Neurology (AAN) Annual Meeting, to be held in San
WASHINGTON , March 31, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (
WASHINGTON , Feb. 24, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of an article entitled "Potential ASO-based personalized treatment for Cha
Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript
10:29pm, Thursday, 13'th Feb 2025
Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Kevin Moran - SVP, CFO & Treasurer Mihael Polymeropoulos - Founder, Presid
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates
06:21pm, Thursday, 13'th Feb 2025
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.04 per share a year ago.
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
04:01pm, Thursday, 13'th Feb 2025
Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023 Q4 2024 Fanapt® net product sales of $26.6 million, +18% compared to Q4 2023 Full year 2024 total revenues of $198.8 million, +3% com
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025
04:30pm, Wednesday, 05'th Feb 2025
Conference Call and Webcast to Follow WASHINGTON , Feb. 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and ful
Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular Psoriasis Vanda expects to immediately begin preparing BLA and MAA applications for the US and EU Anaptys to r
Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis
07:00am, Monday, 27'th Jan 2025
Highlights faulty FDA review WASHINGTON , Jan. 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant development program. Gastroparesis
Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review
04:17pm, Wednesday, 08'th Jan 2025
WASHINGTON , Jan. 8, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) letter to FDA Commissioner highlights faulty gastroparesis NDA review. As previously reported, Vanda has sou
